Publications
5674 Results
- Journal / Conference
- Blood Cancer Journal Aug 7;5:e334
- Year
- 2015
- Research Committee(s)
- Myeloma
- PMID
- PMID26252787
- PMC
- PMC4558587
- Study Number(s)
- S1211
Phase I safety data of lenalidomide, bortezomib, dexamethasone, and eloutuzmab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
- Journal / Conference
- New England Journal of Medicine, Aug 20;373(8):737-746
- Year
- 2015
- Research Committee(s)
- Genitourinary
- PMID
- PMID26244877
- PMC
- PMC4562797
- Study Number(s)
- CTSU/E3805
Chemohormonal therapy in metastatic hormone- sensitive prostate cancer
- Journal / Conference
- Seminars in Oncology, Oct;42(5):724-730
- Year
- 2015
- Research Committee(s)
- Lung
- PMID
- PMID26433553
- PMC
- PMC4681517
- Study Number(s)
- S1400
The master protocol concept
- Journal / Conference
- Journal of Clinical Oncology 33:5s (suppl; abstr 3585); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
- Year
- 2015
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405
- Journal / Conference
- Journal of Clinical Oncology 33:5s (suppl; abstr 3503); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation;
- Year
- 2015
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance)
- Journal / Conference
- Annals of Surgery Sep;262(3):434-439
- Year
- 2015
- Research Committee(s)
- Breast
- PMID
- PMID26222764
- Study Number(s)
- CTSU/C40603
Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast conserving surgery and breast conservation rates: Surgical results from CALGB 40603 (Alliance)
- Journal / Conference
- Journal of Thoracic Oncology, 10(9): S322 (Suppl 2; abst MINI17.02; World Conference on Lung Cancer (WCLC) (September 6-9, 2015, Denver, CO);
- Year
- 2015
- Research Committee(s)
- Lung
- Study Number(s)
- S0709
SWOG 0709: randomized phase II trial of erlotinib vs. erlotinib plus carboplatin/paclitaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) and impaired performance status (PS2) as selected by a serum proteomics assay
- Journal / Conference
- Cancer Epidemiology, Biomarkers & Prevention, Oct;24(10):1507-1515
- Year
- 2015
- Research Committee(s)
- Cancer Control
- PMID
- PMID26269564
- PMC
- PMC4592455
- Study Number(s)
- SWOG-9217
Serum retinol and carotenoid concentrations and prostate cancer risk: results from the prostate cancer prevention trial
- Journal / Conference
- ISOQOL 2015 meeting (October 21-24, 2015, Vancouver, BC, CAN), oral presentation
- Year
- 2015
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/N1048
Compliance and interim results of a cluster-randomized study of clinician-patient shared vs standard reporting of symptomatic adverse events using PRO-CTCAE embedded in the Alliance N1048 PROSPECT rectal cancer clinical trial
- Journal / Conference
- Journal of Clinical Oncology 33:5s (suppl; abstr 3599); American Society of Clinical Oncology Annual Meeting, poster session;
- Year
- 2015
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405